Novo’s Wegovy Beats Lilly’s Zepbound for Heart Health, Study Finds. What It Means for Stocks.

Novo Nordisk’s Wegovy cut the risk of heart attacks, stroke and death by more than Eli Lilly’s weight-loss drug Zepbound, a new study found. Compared with tirzepatide—the active ingredient in Zepbound ... Read More

GoodRx, Novo Nordisk partner to offer Ozempic, Wegovy

Prescription savings platform GoodRx is collaborating with pharma giant Novo Nordisk to make Ozempic and Wegovy pens available to eligible self-paying patients using GoodRx for $499 per month at ... Read More

Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage

Some patients taking GLP-1 drugs for weight loss have been forced to switch to a different medication due to a change in insurance coverage — and they’re not happy about it. As of July 1, CVS Caremark ... Read More

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk’s breakup with Hims

Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the ... Read More

Does Medicare cover Wegovy? Insurance provider could start covering certain weight loss drugs

Medicare could start covering Wegovy for certain senior citizens and other beneficiaries with a history of heart disease now that the US Food and Drug Administration has approved drugmaker Novo ... Read More

Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding

Novo Nordisk's shares plunged more than 20% Tuesday, after the company cut the forecast for its flagship obesity drug. Before the markets opened, the company announced that sales of its obesity ... Read More